• Proprietary Mouse Hybridoma Development

    RAPID PRIME: FUSION IN 19 DAYS, POSITIVE CLONES IN 65 DAYS
  • Pioneers in Rabbit mAb Development

    RECOMBINANT MONOCLONAL ANTIBODY TECHNOLOGY (RMAT)
  • Leaders in Cryopreservation

    PROVIDING CLIENTS WITH PEACE-OF-MIND THROUGH SECURE LN2 STORAGE
  • Direct Access to Our Principal Scientists

    PERSONALIZED SERVICE ON YOUR MOST DIFFICULT PROJECTS

IPA Featured Services

With over 25 years of experience in the custom antibody business, IPA provides high satisfaction through a customized professional approach.
Hybridoma Development
Hybridoma Development

Along with traditional methods of hybridoma development, Rapid Prime is ImmunoPrecise’s proprietary custom mAb development service. This quick and effective immunization strategy coupled with Single-Step cloning, saves weeks in development time. Positive hybridoma clones are identified in 32 days.

Learn More: Hybridoma Development

Rabbit Monoclonals
Rabbit Monoclonals

ImmunoPrecise is excited to offer custom rabbit mAbs using Recombinant Monoclonal Antibody Technology (RMAT). This proprietary technology allows for the screening of the immune repertoire of the rabbit creating the power to select the desired antibody directly from B cells.


Learn More: Recombinant mAb Technology

Cryostorage
Cryostorage

ImmunoPrecise provides you with a secure, off-site storage facility to safeguard your assets. We have the capability to store cell lines, tissues, RNA, DNA, plasmid constructs, antibodies, and many other biological materials.



Learn More: Safeguard Your Valuables

Hybridoma Sequencing
Hybridoma Sequencing

Your monoclonal antibody is extremely valuable, but hybridoma cell lines can become unstable over time and can stop secreting antibody. With ImmunoProtect™, the DNA sequence of your antibody will be determined and can be used to express your mAb recombinantly.


Learn More: Protect Your Valuable Hybridomas

Antibody Generation
Antibody Generation

IPA’s bioreactor process is an excellent animal-free alternative for custom bulk antibody production. One bioreactor flask can produce as much antibody as ascites from 10 to 12 mice. In addition, monoclonal antibody production in bioreactors contains no contaminating host mouse immunoglobulin.


Learn More: Build Your Antibody Stockpile

Antibody Purification
Antibody Purification

IPA offers a selection of purification procedures for isolation of specific antibody from serum, ascites fluid, and concentrated tissue culture supernatant. Purified products undergo a full round of analysis to ensure high quality antibody generation for use in important experiments or downstream manufactured products.

Learn More: Purify Your Antibodies

Start Your Project

We are ready to initiate the immunization phase of your custom antibody development project immediately.

IPA Client Reviews

What our advocates have to say
The ImmunoPrecise ‘rapid-prime’ antibody technology proved pivotal to Acumen’s success, enabling timely identification of the first ADDL selective monoclonal antibodies. Subsequent proof-of-concept studies with our Northwestern colleagues led to our successful Merck collaboration to develop effective therapeutic antibodies for Alzheimer’s disease.
Grant Krafft, PhD, Chairman & Chief Science Officer

Acumen Pharmaceuticals, Inc.

The monoclonal antibodies developed for us by ImmunoPrecise Antibodies Ltd. over the past 5-10 years have been instrumental in providing proof-of-concept data for our research, which in turn has excited considerable commercial interest. Their reagents have always been developed promptly, tested to have the strict specificities we requested, and to have the highest affinities available. We would never consider another company to approach for outsourcing our monoclonal development.
Dr. R.Gorczynski, MD PhD, Professor

University Health Network Toronto

A number of the monoclonal antibodies developed for us by ImmunoPrecise Antibodies Ltd. are currently in use by several of our commercial clients in their rapid, point of care tests for infectious disease detection. This speaks to the fact that these antibodies are of the strictest specificities and highest affinities available.
Douglas McAllister, PhD, President

ViroStat, Inc.